Serum total acid phosphatase for monitoring the clinical course of giant cell tumors of bone - 26 Patients with 5 local recurrences

5Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Background: Giant cell tumor of bone (GCT) is a bone-destroying tumor that sometimes recurs locally after treatment. A recent study showed increased levels of serum total acid phosphatase (TACP). Methods: We assessed TACP in the serum of 26 patients with primary GCT, and in 5 of them who developed a local recurrence. Results: We found a correlation between TACP level in serum and tumor size. TACP levels that were elevated preoperatively in patients with GCT became normalized after surgery, but increased in 3 of the 5 patients with local recurrence. Interpretation: TACP could be used as a tumor marker for monitoring response to treatment of GCT. Copyright © Taylor & Francis 2005.

Cite

CITATION STYLE

APA

Akahane, T., Isobe, K., & Shimizu, T. (2005). Serum total acid phosphatase for monitoring the clinical course of giant cell tumors of bone - 26 Patients with 5 local recurrences. Acta Orthopaedica, 76(5), 651–653. https://doi.org/10.1080/17453670510041727

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free